SYRE fundamentals
An in-depth look to Spyre Therapeutics, Inc. operating, investing, and financing activities
SYRE free cash flow for Q2 24 is -62.25 M USD. For 2023, SYRE free cash flow was -99.91 M USD and operating cash flow was -99.91 M USD.
Q4 '22
Q1 '23
Q2 '23
Q3 '23
Q4 '23
Q1 '24
Q2 '24
0.00
Cash from operating activities
Cash from investing activities
Cash from financing activities
Currency: USD
Q4 '22
Q1 '23
Q2 '23
Q3 '23
Q4 '23
Q1 '24
Q2 '24
TTM